PL406033A1 - Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers - Google Patents

Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers

Info

Publication number
PL406033A1
PL406033A1 PL406033A PL40603313A PL406033A1 PL 406033 A1 PL406033 A1 PL 406033A1 PL 406033 A PL406033 A PL 406033A PL 40603313 A PL40603313 A PL 40603313A PL 406033 A1 PL406033 A1 PL 406033A1
Authority
PL
Poland
Prior art keywords
diagnosing
thyroid
carcinoma
mir
patient
Prior art date
Application number
PL406033A
Other languages
Polish (pl)
Inventor
Krystian Jażdżewski
Anna Wójcicka
Anna Kubiak
Wojciech Gierlikowski
Monika Maciąg
Monika Kolanowska
Agnieszka Czajka
Marta Kotlarek
Michał Świerniak
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Priority to PL406033A priority Critical patent/PL406033A1/en
Priority to PCT/IB2014/066057 priority patent/WO2015071876A2/en
Publication of PL406033A1 publication Critical patent/PL406033A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

Przedmiotem wynalazku jest sposób diagnozowania zmiany chorobowej, takiej jak nowotwór i/lub zmiana łagodna tarczycy u pacjenta, który to sposób obejmuje: - dostarczanie pochodzącej od pacjenta próbki biologicznej, - określanie ilości jednego lub więcej mikroRNA wybranego z grupy obejmującej miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p i miR-182-5p w próbce biologicznej, - porównywanie ekspresji mikroRNA z poziomem ekspresji mikroRNA w grupie kontrolnej, - diagnozowanie wystąpienia nowotworu /i/lub zmiany łagodnej u pacjenta, jeśli poziom ekspresji mikroRNA w próbce biologicznej jest zmieniony względem poziomu ekspresji obserwowanej w próbkach płynów biologicznych w grupie kontrolnej. Przedmiotem wynalazku jest także zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie tarczycy oraz zestaw do diagnozowania zmiany chorobowej.The subject of the invention is a method for diagnosing a lesion such as cancer and / or benign thyroid in a patient, which method comprises: - providing a patient-derived biological sample, - determining the amount of one or more microRNA selected from the group consisting of miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p and miR-182-5p in a biological sample, - comparison of microRNA expression with the level of microRNA expression in the control group, - diagnosing the occurrence of a tumor / and / or benign change in a patient if the level of microRNA expression in a biological sample is changed relative to the level of expression observed in biological fluid samples in the control group. The invention also relates to the use of a microRNA marker for diagnosing a thyroid lesion and a kit for diagnosing a lesion.

PL406033A 2013-11-14 2013-11-14 Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers PL406033A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL406033A PL406033A1 (en) 2013-11-14 2013-11-14 Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers
PCT/IB2014/066057 WO2015071876A2 (en) 2013-11-14 2014-11-14 Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406033A PL406033A1 (en) 2013-11-14 2013-11-14 Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers

Publications (1)

Publication Number Publication Date
PL406033A1 true PL406033A1 (en) 2015-05-25

Family

ID=53058217

Family Applications (1)

Application Number Title Priority Date Filing Date
PL406033A PL406033A1 (en) 2013-11-14 2013-11-14 Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers

Country Status (2)

Country Link
PL (1) PL406033A1 (en)
WO (1) WO2015071876A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
JP6078339B2 (en) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド Methods and compositions for diagnosis of thyroid status
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (en) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res PROSTATE CANCER PROGNOSIS USING BIOMARKERS
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CN110506127B (en) 2016-08-24 2024-01-12 维拉科特Sd公司 Use of genomic tags to predict responsiveness of prostate cancer patients to post-operative radiation therapy
CA3050984A1 (en) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
KR102649965B1 (en) * 2019-01-11 2024-03-22 연세대학교 산학협력단 Composition for Targeting Medullary Thyroid Cancer
RU2705110C1 (en) * 2019-04-10 2019-11-06 Государственное бюджетное учреждение здравоохранения "Краевая клиническая больница N2" Министерства здравоохранения Краснодарского края Method for differential diagnosis of thyroid neoplasms
CN111286538B (en) * 2020-02-13 2023-04-07 朱伟 Circulating miRNA and carcinoembryonic miRNA markers related to pan-tumor auxiliary diagnosis and application thereof
CN114196759B (en) * 2021-12-31 2023-10-20 深圳市海普洛斯生物科技有限公司 Pancreatic cancer biomarker of urine sample and application thereof
CN116769922B (en) * 2023-08-24 2023-11-24 四川大学华西医院 Application of reagent for detecting circulating sEV RNA, kit and diagnostic system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052184A2 (en) 2002-12-12 2004-06-24 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
US20060160114A1 (en) 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance
US7943318B2 (en) 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
CA2676113C (en) 2007-07-25 2014-07-08 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2009143379A2 (en) 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
CA2765870A1 (en) 2009-06-19 2010-12-23 Leroi V. Desouza Renal cell carcinoma biomarkers
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
US20130237590A1 (en) 2010-07-15 2013-09-12 Mayo Foundation For Medical Education And Research Assessing thyroid neoplasms
EP2772550B1 (en) * 2010-11-17 2017-03-29 Interpace Diagnostics, LLC Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
AU2012230835B2 (en) * 2011-03-22 2016-05-05 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
EP2505664B1 (en) * 2011-03-30 2014-12-03 Universität Leipzig Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB)
WO2013063544A1 (en) * 2011-10-27 2013-05-02 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors

Also Published As

Publication number Publication date
WO2015071876A3 (en) 2015-08-27
WO2015071876A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
PL406033A1 (en) Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers
PL405648A1 (en) Method for diagnosing primary hepatic carcinoma, application of microRNA marker for diagnosing the lesion within liver, assessment of the progression of disease and evaluation of patient's vulnerability and/or disease to the proposed treatment and diagnostic set containing such same markers
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
CL2008001517A1 (en) Device for determining the risk of melanoma progression comprising oligonucleotides of one or more melanoma prognostic markers (mpms) chosen from a selection group; procedure for determining the prognosis of melanoma in a patient; Procedure for determining the suitability of a melanoma patient for a drug trial.
PH12017501841A1 (en) Method for discriminating symptom of hepatic disease
BR112016007864A2 (en) Method for cancer prognosis and metastasis treatment
BR112014030750A2 (en) METHOD FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER METASTASIS
PH12015501868A1 (en) Inhibitors of histone demethylases
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
BR112015008255A2 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
MX2022012384A (en) Compositions and methods for screening mutations in thyroid cancer.
BRPI0901277A2 (en) biopsy site marker applicator and method
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
MX2017015210A (en) Compositions and methods for screening solid tumors.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
BR112015009438A2 (en) use of a ly75 binding antibody, method of detecting, diagnosing and / or evaluating or monitoring cancer progression and method for identifying an agent for the treatment or prophylaxis of a cancer
EA201490946A1 (en) METHOD OF QUANTITATIVE EVALUATION OF CANCER TREATMENT
BR112016022407A2 (en) compositions and methods related to prostate cancer diagnosis
EP3495502A3 (en) Biomarkers for premature birth
BR112015029550A2 (en) ANTI-VEGF ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, DIAGNOSIS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE CONTAINING THE SAME
MX359376B (en) Method and kit for determination of free copper in serum.
WO2014181960A3 (en) Fluorescent probe sensing tyrosine kinase and use thereof